The integration of precision genomics and next-generation gene therapy platforms is fundamentally redefining therapeutic possibilities for rare, monogenic diseases. Over 80% of identified rare conditions stem from single-gene mutations, making them ideal candidates for targeted genetic interventions. Adeno-associated virus (AAV) vectors, lentiviral gene insertion, and CRISPR-Cas9 gene editing...